BSH 2019 | Inhibition of C3 with APL-2 in autoimmune hemolytic anemia to reduce hemolysis

Name: Inhibition of C3 with APL-2 in autoimmune hemolytic anemia to reduce hemolysis
Uploaded: 2019-04-02T00:00:00.000Z
Duration: 1 min 53 s
Description: Bruno Fattizzo, MD, of the University of Milan, Milan, Italy, speaks at the British Society for Haematology (BSH) 2019 Annual Meeting, held in Glasgow, UK. He discusses his research on the effects of pegcetacoplan, a C3 inhibitor, on hemolysis in autoimmune hemolytic anemia (AIHA).

Bruno Fattizzo • 2 Apr 2019

BSH 2019

Anemias Pegcetacoplan

Bruno Fattizzo, MD, of the University of Milan, Milan, Italy, speaks at the British Society for Haematology (BSH) 2019 Annual Meeting, held in Glasgow, UK. He discusses his research on the effects of pegcetacoplan, a C3 inhibitor, on hemolysis in autoimmune hemolytic anemia (AIHA).